2 April 2024 - Roche designed its trial for both approval and health technology assessments but the analyses planned for ...
1 March 2024 - Patients with inoperable or metastatic uveal melanoma survive longer with the new therapy than with other therapy ...
18 January 2024 - Since July 2023, there has been one in Germany for patients who suffer from acute myeloid leukaemia ...
15 November 2023 - Two randomised controlled studies in the third and fourth lines for colorectal and breast cancer each show ...
5 October 2023 - Due to legal requirements, the Federal Joint Committee (G-BA) has completed the re-evaluation process for belantamab mafodotin ...
2 May 2023 - For patients with advanced HER2 low breast cancer, IQWiG sees an additional benefit that is partly considerable ...
17 April 2023 - Younger treatment naïve patients benefit. No relevant data were presented for previously treated patients. ...
15 March 2023 - For adults with relapsed/refractory chronic lymphocytic leukaemia who have not yet received a BTK or BCL2 inhibitor, ...
2 January 2023 - Advantages in overall survival and in relapses often only become apparent after a long period of ...
5 December 2022 - National health technology assessments across Europe show differences in evidentiary requirements from assessments by the EMA, affecting ...
1 December 2022 - Adjuvant treatment with olaparib can prolong life and prevent recurrence in early breast cancer. However, it ...
2 November 2022 - There is a hint of a major added benefit compared to chemotherapy with cisplatin or carboplatin, each ...
5 October 2022 - For post-menopausal women with hormone receptor positive, HER2 negative breast cancer in the first line, there is ...
1 August 2022 - The additional clinical benefit cannot be quantified because the data on health status and health-related quality ...
19 May 2022 - The Federal Joint Committee (G-BA) has rated the patient-relevant additional benefit of two active ingredients for cancer ...